These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37401345)

  • 1. The role of lebrikizumab in the treatment of atopic dermatitis in the adult population.
    Prajapati S; Fardos M; Desai AD; Feldman SR
    Immunotherapy; 2023 Sep; 15(13):981-991. PubMed ID: 37401345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
    Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
    Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment.
    Silverberg JI; Wollenberg A; Stein Gold L; Del Rosso J; Yosipovitch G; Lio P; Carrascosa JM; Gallo G; Ding Y; Xu Z; Casillas M; Pierce E; Agell H; Ständer S
    Dermatol Ther (Heidelb); 2024 Aug; 14(8):2249-2260. PubMed ID: 39123054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
    Stein Gold L; Thaçi D; Thyssen JP; Gooderham M; Laquer V; Moore A; Natalie CR; Zhao F; Meskimen E; Elmaraghy H; Montmayeur S; Gallo G; Jimenez G; de Bruin-Weller M
    Am J Clin Dermatol; 2023 Jul; 24(4):595-607. PubMed ID: 37195407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
    Silverberg JI; Guttman-Yassky E; Thaçi D; Irvine AD; Stein Gold L; Blauvelt A; Simpson EL; Chu CY; Liu Z; Gontijo Lima R; Pillai SG; Seneschal J;
    N Engl J Med; 2023 Mar; 388(12):1080-1091. PubMed ID: 36920778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
    Blauvelt A; Thyssen JP; Guttman-Yassky E; Bieber T; Serra-Baldrich E; Simpson E; Rosmarin D; Elmaraghy H; Meskimen E; Natalie CR; Liu Z; Xu C; Pierce E; Morgan-Cox M; Garcia Gil E; Silverberg JI
    Br J Dermatol; 2023 May; 188(6):740-748. PubMed ID: 36994947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2).
    Simpson E; Fernández-Peñas P; de Bruin-Weller M; Lio PA; Chu CY; Ezzedine K; Agell H; Casillas M; Ding Y; Yang FE; Pierce E; Bieber T
    Adv Ther; 2024 Sep; ():. PubMed ID: 39249591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
    Simpson EL; Flohr C; Eichenfield LF; Bieber T; Sofen H; Taïeb A; Owen R; Putnam W; Castro M; DeBusk K; Lin CY; Voulgari A; Yen K; Omachi TA
    J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials.
    Hebert AA; Flohr C; Hong HC; Irvine AD; Pierce E; Elmaraghy H; Pillai S; Dawson Z; Chen S; Armengol C; Siegfried E; Weidinger S
    J Dermatolog Treat; 2024 Dec; 35(1):2324833. PubMed ID: 38735650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
    Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
    J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of nemolizumab in the treatment of atopic dermatitis for the adult population.
    Prajapati S; Flemming JP; Khan D; Han H; How B; Rozenberg SS; Feldman SR
    Immunotherapy; 2024; 16(14-15):925-935. PubMed ID: 39119679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis.
    Loh TY; Hsiao JL; Shi VY
    J Asthma Allergy; 2020; 13():109-114. PubMed ID: 32104006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.
    Lio PA; Armstrong A; Gutermuth J; Nosbaum A; Sofen H; Gil EG; Casillas M; Chen S; Sun L; Pierce E; Elmaraghy H; Dawson Z; Torres T
    Dermatol Ther (Heidelb); 2024 Jul; 14(7):1929-1943. PubMed ID: 38922484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis.
    Rand K; Ramos-Goñi JM; Akmaz B; Solé-Feu L; Armario-Hita JC
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):169-182. PubMed ID: 37897645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
    Simpson EL; Gooderham M; Wollenberg A; Weidinger S; Armstrong A; Soung J; Ferrucci S; Lima RG; Witte MM; Xu W; ElMaraghy H; Natalie CR; Pierce E; Blauvelt A;
    JAMA Dermatol; 2023 Feb; 159(2):182-191. PubMed ID: 36630140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.